Obesity in cystic fibrosis

The prevalence of obesity in patients with cystic fibrosis (CF) is increasing and around one-third of adults with CF are now overweight or obese. The causes of excess weight gain in CF are likely multifactorial, including: adherence to the high-fat legacy diet, reduced exercise tolerance, therapeuti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Katherine A. Kutney, Zahrae Sandouk, Marisa Desimone, Amir Moheet
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Cystic fibrosis Obesity Cystic fibrosis related diabetes Cardiovascular disease CFTR modulator Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/0b0aaaa0c964486581fda443ba1c7219
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0b0aaaa0c964486581fda443ba1c7219
record_format	dspace
spelling	oai:doaj.org-article:0b0aaaa0c964486581fda443ba1c72192021-11-24T04:31:18ZObesity in cystic fibrosis2214-623710.1016/j.jcte.2021.100276https://doaj.org/article/0b0aaaa0c964486581fda443ba1c72192021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2214623721000284https://doaj.org/toc/2214-6237The prevalence of obesity in patients with cystic fibrosis (CF) is increasing and around one-third of adults with CF are now overweight or obese. The causes of excess weight gain in CF are likely multifactorial, including: adherence to the high-fat legacy diet, reduced exercise tolerance, therapeutic advances, and general population trends. Increased weight has generally been considered favorable in CF, correlating with improved pulmonary function and survival. While the optimal BMI for overall health in CF is unknown, most studies demonstrate minimal improvement in pulmonary function when BMI exceeds 30 kg/m2. Dyslipidemia and cardiovascular disease are important co-morbidities of obesity in the general population, but are uncommon in CF. In people with CF, obesity is associated with hypertension and higher cholesterol levels. With longer life expectancy and rising obesity rates, there may be an increase in cardiovascular disease among people with CF in coming years. Overweight CF patients are more likely to be insulin resistant, taking on features of type 2 diabetes. Treating obesity in people with CF requires carefully weighing the metabolic risks of overnutrition with the impact of low or falling BMI on lung function. This article describes current knowledge on the epidemiology, causes, consequence, and treatment of obesity in people with CF.Katherine A. KutneyZahrae SandoukMarisa DesimoneAmir MoheetElsevierarticleCystic fibrosisObesityCystic fibrosis related diabetesCardiovascular diseaseCFTR modulatorDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENJournal of Clinical & Translational Endocrinology, Vol 26, Iss , Pp 100276- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cystic fibrosis Obesity Cystic fibrosis related diabetes Cardiovascular disease CFTR modulator Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	Cystic fibrosis Obesity Cystic fibrosis related diabetes Cardiovascular disease CFTR modulator Diseases of the endocrine glands. Clinical endocrinology RC648-665 Katherine A. Kutney Zahrae Sandouk Marisa Desimone Amir Moheet Obesity in cystic fibrosis
description	The prevalence of obesity in patients with cystic fibrosis (CF) is increasing and around one-third of adults with CF are now overweight or obese. The causes of excess weight gain in CF are likely multifactorial, including: adherence to the high-fat legacy diet, reduced exercise tolerance, therapeutic advances, and general population trends. Increased weight has generally been considered favorable in CF, correlating with improved pulmonary function and survival. While the optimal BMI for overall health in CF is unknown, most studies demonstrate minimal improvement in pulmonary function when BMI exceeds 30 kg/m2. Dyslipidemia and cardiovascular disease are important co-morbidities of obesity in the general population, but are uncommon in CF. In people with CF, obesity is associated with hypertension and higher cholesterol levels. With longer life expectancy and rising obesity rates, there may be an increase in cardiovascular disease among people with CF in coming years. Overweight CF patients are more likely to be insulin resistant, taking on features of type 2 diabetes. Treating obesity in people with CF requires carefully weighing the metabolic risks of overnutrition with the impact of low or falling BMI on lung function. This article describes current knowledge on the epidemiology, causes, consequence, and treatment of obesity in people with CF.
format	article
author	Katherine A. Kutney Zahrae Sandouk Marisa Desimone Amir Moheet
author_facet	Katherine A. Kutney Zahrae Sandouk Marisa Desimone Amir Moheet
author_sort	Katherine A. Kutney
title	Obesity in cystic fibrosis
title_short	Obesity in cystic fibrosis
title_full	Obesity in cystic fibrosis
title_fullStr	Obesity in cystic fibrosis
title_full_unstemmed	Obesity in cystic fibrosis
title_sort	obesity in cystic fibrosis
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/0b0aaaa0c964486581fda443ba1c7219
work_keys_str_mv	AT katherineakutney obesityincysticfibrosis AT zahraesandouk obesityincysticfibrosis AT marisadesimone obesityincysticfibrosis AT amirmoheet obesityincysticfibrosis
_version_	1718415957523693568

Obesity in cystic fibrosis

Ejemplares similares